Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Inhibition of Wnt Signaling By Dimethyl Fumarate Results in in Vitro and in Vivo Clearance of Chronic Lymphocytic Leukemia Cells and Has Additive Activity with Ibrutinib

Christina C.N. Wu, PhD, Fitzgerald Lao, Hongying Li, PhD, Laura Rassenti, PhD, Thomas J. Kipps, MD, Karen Messer, PhD, Dennis A. Carson, MD, Michael Y. Choi, MD

Blood (2014) 124 (21): 4683.

https://doi.org/10.1182/blood.V124.21.4683.4683

Published: 2014

Journal Articles

Dynamics Changes in CCL3 and CCL4 Plasma Chemokine Levels in Patients with Chronic Lymhocytic Leukemia (CLL) Managed with Observation

Mariela Sivina, PhD, Lillian Werner, Laura Rassenti, PhD, William G. Wierda, MD PhD, Michael J. Keating, MD, Susan O'Brien, MD, Donna Neuberg, ScD, Thomas J. Kipps, MD PhD, Jan A. Burger, MD PhD

Blood (2014) 124 (21): 5640.

https://doi.org/10.1182/blood.V124.21.5640.5640

Published: 2014

Journal Articles

A Complementary Role of High Throughput Sequencing and Multiparameter Cytometry for Minimal Residual Disease (MRD) Detection in Chronic Lymphocytic Leukemia (CLL):an European Research Initiative (ERIC) Study

Andy Rawstron, PhD, Claudia Fazi, PhD, Neus Villamor, MD PhD, Julio Delgado, MD PhD, Remi Letestu, MD PhD, Florence Cymbalista, MD, Carlos Palacio, Francesc Bosch, MD PhD, Ruth M De Tute, MSc, Stuart Liptrot, David O'Brien, FAMLs, Martin Spacek, MD, PhD, Johan Dobber, Arnon P. Kater, MD PhD, Peter C Gambell, David A Westerman, MBBS, FRACP, FRCPA, Asha Soosapilla, Stephen P. Mulligan, MBBS, PhD FRACP, FRCPA, Gerard Lozanski, MD, Ke Lin, PhD, Andrew R Pettitt, MRCP, PhD, Gabi Brachtl, Alexander Egle, MD, David W Williamson, PhD, Catherine M Sanders, PhD, Harlan Robins, PhD, Justin Boysen, Tait D. Shanafelt, MD, Curtis A. Hanson, MD, Jeffrey L. Jorgensen, MD PhD, William G. Wierda, MD PhD, Constance Yuan, MD PhD, Maryalice Stetler-Stevenson, MD PhD, Laura Rassenti, PhD, H. Elizabeth Broome, MD, Thomas J. Kipps, MD PhD, Mathieu Hauwel, Iuri Marinov, Fiona E. Craig, MBBS, Nomdedeu Josep, Carol Moreno, MD, Olga Stehlikova, MSc., Michael Doubek, Sarka Pospisilova, Prof., Dr., PhD, Karl-Anton Kreuzer, MD, Michael Hallek, MD, Peter Hillmen, MBChB, PhD, Emili Montserrat, MD PhD, Paolo Ghia, MD

Blood (2014) 124 (21): 1976.

https://doi.org/10.1182/blood.V124.21.1976.1976

Published: 2014

Journal Articles

Kinetic Measurement of Leukemia-Cell Proliferation Rate By Deuterium Labeling Predicts Time to Initial Treatment of Patients with Chronic Lymphocytic Leukemia

Blood (2014) 124 (21): 829.

https://doi.org/10.1182/blood.V124.21.829.829

Published: 2014

Journal Articles

Allele-Specific Loss Of The Mir-15a/16-1 Cluster Correlates With ZAP70 Expression In CLL Patients With 13q Deletion

Blood (2013) 122 (21): 3753.

https://doi.org/10.1182/blood.V122.21.3753.3753

Published: 2013

Journal Articles

Lenalidomide and Rituximab For The Treatment Of Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia: Results Of Planned Interim Analysis

Michael Y. Choi, MD, Januario E. Castro, M.D., Sheila Hoff, RN, Hongying Li, PhD, Laura Rassenti, PhD, Danelle F. James, M.D., M.A.S., Karen Messer, PhD, Thomas J. Kipps, MD, PhD

Blood (2013) 122 (21): 5299.

https://doi.org/10.1182/blood.V122.21.5299.5299

Published: 2013

Journal Articles

A6 Peptide Is Selectively Cytotoxic For Chronic Lymphocytic Leukemia Cells

Suping Zhang, PhD, Hsien Lai, BS, Grace Liu, Laura Rassenti, PhD, Michael Y. Choi, MD, Stephen B Howell, MD, Malcolm Finlayson, PhD, Thomas J. Kipps, MD, PhD

Blood (2013) 122 (21): 5303.

https://doi.org/10.1182/blood.V122.21.5303.5303

Published: 2013

Journal Articles

Heterogeneity and Evolution Of DNA Methylation In Chronic Lymphocytic Leukemia

Christopher C Oakes, Ph.D, Rainer Claus, MD, Lei Gu, Yassen Assenov, Jennifer Hüllein, Manuela Zucknick, David Brocks, Olga Bogatyrova, Christopher R. Schmidt, Laura Rassenti, PhD, Thomas J. Kipps, MD, PhD, Daniel Mertens, PhD, Peter Lichter, PhD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD, John C. Byrd, MD, Thorsten Zenz, MD, Christoph Plass, PhD

Blood (2013) 122 (21): 1626.

https://doi.org/10.1182/blood.V122.21.1626.1626

Published: 2013

Journal Articles

Preclinical Development Of ROR1 Peptide Based Vaccine With Activity Against Chronic Lymphocytic Leukemia In ROR1 Transgenic Mice

Jian Yu, PhD, Bing Cui, Ph.D., George F. Widhopf, II, PhD, Liguang Chen, MD, PhD, Laura Rassenti, PhD, Zhengran Wang, BS, Shuyu Ma, BS, Tomoko Hayashi, M.D., Ph.D., Dennis A. Carson, M.D., Thomas J. Kipps, MD, PhD

Blood (2013) 122 (21): 4174.

https://doi.org/10.1182/blood.V122.21.4174.4174

Published: 2013

Journal Articles

TP53 Mutation or Deletion and Efficacy with Single-Agent Lenalidomide in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) (CC-5013-CLL-009 Study)

Andreas Bühler, Clemens Wendtner, MD, Michael Hallek, Thomas J. Kipps, MD, PhD, Laura Rassenti, PhD, Graeme Fraser, Anne-Sophie Michallet, Peter Hillmen, Jan Duerig, MD, Stephanie A. Gregory, Matt Kalaycio, MD, Therese Aurran-Schleinitz, Livio Trentin, Brendan Purse, Jennie Zhang, Jay Mei, MD, Stephan Stilgenbauer, MD

Blood (2013) 122 (21): 1638.

https://doi.org/10.1182/blood.V122.21.1638.1638

Published: 2013

Journal Articles

A Cyclopropane-Derived Stable Analog Of Fd-895 Induces Apoptosis and Inhibition Of mRNA Splicing In Lymphoma and Chronic Lymphocytic Leukemia: A Novel Therapeutic Approach

Deepak Kumar, PhD, Manoj Kumar Kashyap, PhD, Ide Spaanderman, BS, Reymundo Villa, PhD, Laura Rassenti, PhD, James La Clair, PhD, Michael D. Burkat, PhD, Thomas J. Kipps, MD, PhD, Januario E. Castro, M.D.

Blood (2013) 122 (21): 2884.

https://doi.org/10.1182/blood.V122.21.2884.2884

Published: 2013

Journal Articles

Trisomy 12 CLL Cells Have High Surface Expression Of Integrins Involved In Lymphocyte Trafficking But This Does Not Translate Into Improved LFA-1-Mediated Motility

Conor J. O'Donovan, Alan G. Ramsay, PhD, Fabienne McClanahan, MD, Laura Rassenti, PhD, Thomas J. Kipps, MD, PhD, John Gribben, MD, DSc, John C. Riches, MD

Blood (2013) 122 (21): 4159.

https://doi.org/10.1182/blood.V122.21.4159.4159

Published: 2013

Journal Articles

Interactome-Based Molecular Prognosis of Chronic Lymphocytic Leukemia

Han-Yu Chuang, Laura Rassenti, PhD, Trey Ideker, PhD, Thomas J. Kipps, MD, PhD

Blood (2008) 112 (11): 545.

https://doi.org/10.1182/blood.V112.11.545.545

Published: 2008

Journal Articles

Characteristics of Familial CLL Evaluated in the CLL Research Consortium Cohort

Jennifer R Brown, MD, PhD, Laura Rassenti, PhD, Donna Neuberg, ScD, Andrew Greaves, John C. Byrd, Michael R Grever, John G. Gribben, MD, DSc, Neil E. Kay, Michael Keating, MB, BS, Kanti R. Rai, MD, William G. Wierda, Thomas J Kipps

Blood (2008) 112 (11): 3125.

https://doi.org/10.1182/blood.V112.11.3125.3125

Published: 2008

Journal Articles

Early Events in the Clonal Evolution in Patients with Chronic Lymphocytic Leukemia Carrying TP53 Mutations and 17p Deletion

Emanuela M. Ghia, PhD, Laura Rassenti, PhD, Thomas J Kipps, MD, PhD

Blood (2008) 112 (11): 4165.

https://doi.org/10.1182/blood.V112.11.4165.4165

Published: 2008

Journal Articles

The Relative Dependency of Chronic Lymphocytic Leukemia (CLL) Cells on Nurselike Cells for in Vitro Survival Is Associated with Overall Survival in Previously Untreated CLL Patients

Danelle James, M.D., Sonia Jain, PhD, Maryann Betty, Harrison Malone, Andrew Greaves, Laura Rassenti, PhD, Thomas J. Kipps, MD, PhD

Blood (2008) 112 (11): 4169.

https://doi.org/10.1182/blood.V112.11.4169.4169

Published: 2008

Journal Articles

Family-Associated Monoclonal B Lymphocytosis Is Commonly Oligoclonal and Expresses Markers Associated with Adverse Risk in CLL

Mark C Lanasa, MD, PhD, Sallie D Allgood, MS, Susan L. Slager, PhD, Nicola Camp, PhD, Logan Spector, PhD, Laura Rassenti, PhD, Neil E. Kay, Jon P Gockerman, MD, Alicia Volkheimer, MS, Barbara K Goodman, PhD, Sara Strom, PhD, Timothy Call, MD, James Cerhan, MD, PhD, Jose F Leis, MD, PhD, Lynn Goldin, PhD, Gerald Marti, MD, PhD, J Brice Weinberg, MD, Neil Caporaso, MD, Marc C. Levesque, MD, PhD

Blood (2008) 112 (11): 3144.

https://doi.org/10.1182/blood.V112.11.3144.3144

Published: 2008

Journal Articles

Detection of Minimal Residual Disease in Chronic Lymphocytic Leukemia with Monoclonal Antibodies Specific for CD5, CD10, CD19, and ROR1.

H. Elizabeth Broome, MD, Laura Rassenti, PhD, Jack D. Bui, MD, PhD, Lilly Meyer, Thomas J. Kipps, MD, PhD

Blood (2008) 112 (11): 2079.

https://doi.org/10.1182/blood.V112.11.2079.2079

Published: 2008

Journal Articles

TCL1 Expression in Chronic Lymphocytic Leukemia Correlates with the Intensity of 11q Deletions and ZAP-70.

Laura Rassenti, PhD, L. Huynh, B.S., G.W. Basak, MD, PhD, E.M. Ghia, PhD, D. Van Dyke, PhD, N. Heerema, PhD, D. Zahrieh, PhD, P. DalCin, PhD, M.L. Dell’Aquila, PhD, P. Koduru, PhD, J.C. Byrd, MD, N.E. Kay, MD, K.R. Rai, MD, J.R. Brown, MD, PhD, W.W. Wierda, MD, PhD, A.W. Greaves, B.S., Thomas J. Kipps, MD, PhD

Blood (2007) 110 (11): 2068.

https://doi.org/10.1182/blood.V110.11.2068.2068

Published: 2007

Journal Articles

IgVH Mutational Status Does Not Affect Complete Remission Rate but Is Associated with Reduced Remission Duration in CLL Patients Treated with Fludarabine, Cyclophosphamide and Rituximab (FCR)-Based Therapy.

Katherine I. Lin, MBBS, BND, Constantine S. Tam, MBBS, Lynne V. Abruzzo, MD, William Wierda, MD, Lynn Barron, Susan O’Brien, MD, Thomas Kipps, MD, Laura Rassenti, PhD, Susan Lerner, MS, Hagop Kantarjian, MD, Michael J. Keating, MD

Blood (2007) 110 (11): 753.

https://doi.org/10.1182/blood.V110.11.753.753

Published: 2007

NARROW

Inhibition of Wnt Signaling By Dimethyl Fumarate Results in in Vitro and in Vivo Clearance of Chronic Lymphocytic Leukemia Cells and Has Additive Activity with Ibrutinib

Dynamics Changes in CCL3 and CCL4 Plasma Chemokine Levels in Patients with Chronic Lymhocytic Leukemia (CLL) Managed with Observation

A Complementary Role of High Throughput Sequencing and Multiparameter Cytometry for Minimal Residual Disease (MRD) Detection in Chronic Lymphocytic Leukemia (CLL):an European Research Initiative (ERIC) Study

Kinetic Measurement of Leukemia-Cell Proliferation Rate By Deuterium Labeling Predicts Time to Initial Treatment of Patients with Chronic Lymphocytic Leukemia

Allele-Specific Loss Of The Mir-15a/16-1 Cluster Correlates With ZAP70 Expression In CLL Patients With 13q Deletion

Lenalidomide and Rituximab For The Treatment Of Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia: Results Of Planned Interim Analysis

A6 Peptide Is Selectively Cytotoxic For Chronic Lymphocytic Leukemia Cells

Heterogeneity and Evolution Of DNA Methylation In Chronic Lymphocytic Leukemia

Preclinical Development Of ROR1 Peptide Based Vaccine With Activity Against Chronic Lymphocytic Leukemia In ROR1 Transgenic Mice

TP53 Mutation or Deletion and Efficacy with Single-Agent Lenalidomide in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) (CC-5013-CLL-009 Study)

A Cyclopropane-Derived Stable Analog Of Fd-895 Induces Apoptosis and Inhibition Of mRNA Splicing In Lymphoma and Chronic Lymphocytic Leukemia: A Novel Therapeutic Approach

Trisomy 12 CLL Cells Have High Surface Expression Of Integrins Involved In Lymphocyte Trafficking But This Does Not Translate Into Improved LFA-1-Mediated Motility

Interactome-Based Molecular Prognosis of Chronic Lymphocytic Leukemia

Characteristics of Familial CLL Evaluated in the CLL Research Consortium Cohort

Early Events in the Clonal Evolution in Patients with Chronic Lymphocytic Leukemia Carrying TP53 Mutations and 17p Deletion

The Relative Dependency of Chronic Lymphocytic Leukemia (CLL) Cells on Nurselike Cells for in Vitro Survival Is Associated with Overall Survival in Previously Untreated CLL Patients

Family-Associated Monoclonal B Lymphocytosis Is Commonly Oligoclonal and Expresses Markers Associated with Adverse Risk in CLL

Detection of Minimal Residual Disease in Chronic Lymphocytic Leukemia with Monoclonal Antibodies Specific for CD5, CD10, CD19, and ROR1.

TCL1 Expression in Chronic Lymphocytic Leukemia Correlates with the Intensity of 11q Deletions and ZAP-70.

IgVH Mutational Status Does Not Affect Complete Remission Rate but Is Associated with Reduced Remission Duration in CLL Patients Treated with Fludarabine, Cyclophosphamide and Rituximab (FCR)-Based Therapy.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only